AI Article Synopsis
- The study examined how octreotide, a somatostatin analogue, affects tear secretion in rats.
- Rats were divided into four groups and underwent treatments, with one group receiving saline and others receiving varying doses of octreotide and acetylcholine.
- Results showed that while acetylcholine increased tear secretion, octreotide reduced it, and the combination of octreotide and acetylcholine further decreased tear production compared to acetylcholine alone.
- The conclusion indicates that octreotide effectively inhibits acetylcholine-stimulated tear secretion in rats.
Article Abstract
Purpose: In this study we investigated the effect of a somatostatin analogue, octreotide, (SMS 201-995) on tear secretion in rats.
Method: The animals were anaesthetized intraperitoneally (ip) with urethan (1.2 g/kg) The drugs were injected subcutaneously (sc.). Tear samples were collected by folding a 5 mm section of the Schirmer strip over the lower lid margin to absorb tear fluid from the lower conjunctival sac for 5 mm. Forty animals were divided into four groups (n = 10). Group I (control) received 1 ml of saline, group 2 received 100 microg/kg of SMS 201-995, group 3 received 50 microg/kg of acetylcholine (Ach), group 4 received 100 microg/kg of SMS 201-995 and 30 min later 50 microg/kg of Ach. At t = 0 the local anesthetic proparacain HCI was instilled onto the ocular surface to minimize reflex secretion. Baseline secretion was measured before administering the various treatments.
Results: While Ach alone significantly increased tear secretion, SMS 201-995 reduced it compared to saline (control) (p<0.0001, p<0.001, respectively). SMS 201-995 combined with Ach decreased tear secretion compared to Ach alone (p<0.03).
Conclusion: SMS 201-995 significantly inhibits Ach stimulated tear secretion in rats.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1006171323980 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of severe post-bariatric hypoglycaemia with octreotide delivered via a Tandem t:slim insulin pump.
BMJ Case Rep
January 2025
Diabetes, Greenlane Hospital, Auckland, Auckland, New Zealand.
A woman in her 40s presented with severe post-bariatric hypoglycaemia that persisted despite nutritional therapy and pharmacological therapy with acarbose and subcutaneous octreotide with meals. The nutritional limitations were difficult to sustain, and she developed adverse effects to the pharmacological therapy, and hence, doses could not be increased. She was subsequently treated with subcutaneous octreotide via an insulin pump, with a continuous basal rate and additional bolus doses with meals.
View Article and Find Full Text PDFUpper Gastrointestinal Bleeding: A Retrospective, Single-Center Experience on the Role of Endoscopy and Outcomes.
J Clin Med Res
January 2025
Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden.
Background: Upper gastrointestinal bleeding (UGIB) is a common and potentially fatal medical emergency. This study aimed to investigate the frequency, causes, outcomes, and efficacy of endoscopy in the treatment of UGIB at King Fahad Central Hospital in Jazan, Saudi Arabia.
Methods: Between January 2017 and December 2023, a retrospective study was performed including all hospitalized patients with UGIB.
Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance.
Pharmaceutics
December 2024
Pharmathen SA, 31 Spartis Str., 14452 Metamorfosi Attica, Greece.
Regulatory authorities typically require bioequivalence to be demonstrated by comparing pharmacokinetic parameters like area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C). Because in certain cases, AUC and C alone may not be adequate to identify formulation differences in early and/or late segments of the dosing interval, partial AUCs (pAUCs) have been proposed as additional metrics to evaluate bioequivalence. Even though cut-off points for pAUCs are usually decided based on clinical relevance, the identification of the correct cut-off range remains elusive in many other cases and tends to contribute to increased pAUC estimate variabilities.
View Article and Find Full Text PDFDifferential Impact of Medical Therapies for Acromegaly on Glucose Metabolism.
Int J Mol Sci
January 2025
Endocrinology Unit, Department of Internal Medicine and Medical Specialties, School of Medical and Pharmaceutical Sciences, University of Genova, 16132 Genova, Italy.
Acromegaly is a rare endocrine disorder caused by excessive growth hormone (GH) production, due, in the vast majority of cases, to the presence of a GH-secreting pituitary tumour. The chronic elevation of GH and the resulting high circulating levels of insulin-like growth factor-1 (IGF-1) cause the characteristic tissue overgrowth and a number of associated comorbidities, including several metabolic changes, such as glucose intolerance and overt diabetes mellitus (DM). Elevated GH concentrations directly attenuate insulin signalling and stimulate lipolysis, decreasing glucose uptake in peripheral tissues, thus leading to the development of impaired glucose tolerance and DM.
View Article and Find Full Text PDFASO Author Reflections: The Effects of Perioperative Corticosteroids on Postoperative Complications After Pancreatoduodenectomy: A Debated Topic of Systematic Review and Meta-analysis.
Ann Surg Oncol
January 2025
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Introduction: Pancreatoduodenectomy (PD) is a complex surgery with high morbidity and mortality, often associated with complications like post-pancreatectomy hemorrhage (PPH) and postoperative pancreatic fistulas (POPF). The corticosteroids administered intraoperatively has been shown to improve postoperative outcomes in patients undergoing surgery. However, their impact on complications following PD remains controversial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!